跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

M-083

Supelco

哌甲酯 盐酸盐 溶液

(Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C14H20ClNO2
CAS号:
298-59-9
分子量:
269.77
MDL编号:
MFCD00058191
UNSPSC代码:
41116107
PubChem化学物质编号:
329817833
NACRES:
NA.24
价格与库存信息目前不能提供

等级

certified reference material

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

forensics and toxicology

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

Cl.COC(=O)C(C1CCCCN1)c2ccccc2

InChI

1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H

InChI key

JUMYIBMBTDDLNG-UHFFFAOYSA-N

基因信息

human ... SLC6A2(6530) , SLC6A3(6531)

相关类别

一般描述

哌醋甲酯是一种精神刺激药，用于注意力缺陷多动症（ADHD），心动过速和嗜眠症的治疗。该经认证的加标溶液®适用于尿液药物测试、临床毒理学和法医分析的LC/MS或GC/MS应用。哌醋甲酯以商品名Concerta®和Ritalin®出售。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Concerta is a registered trademark of ALZA Corporation
Ritalin is a registered trademark of Novartis Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Liv Larsen Stray et al.
Behavioral and brain functions : BBF, 9, 18-18 (2013-05-07)
Most children who are diagnosed with attention deficit-hyperactivity disorder (ADHD) have moderate-to-severe motor problems using the Motor Function Neurological Assessment battery (MFNU). The MFNU focuses on specific muscle adjustment problems associated with ADHD, especially motor inhibition problems and high muscle
Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Hartmut Heinrich et al.
JAMA psychiatry, 70(5), 545-545 (2013-05-03)
Methylphenidate: trismus.
Prescrire international, 22(140), 185-185 (2013-08-21)
Methylphenidate in the management of cancer-related fatigue.
Patrick C Stone
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(19), 2372-2373 (2013-05-22)
Evert J Semeijn et al.
Journal of the American Geriatrics Society, 61(6), 882-887 (2013-05-29)
To increase insight into the effect of attention-deficit/hyperactivity disorder (ADHD) on health in general in older adults. Two-phase sampling side-study. Longitudinal Aging Study Amsterdam (LASA). Two hundred twenty-three randomly selected LASA respondents. Information was collected during home visits on physical
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持